Maropost bolsters product leadership team to accelerate innovation and growth
21.5.2024 20:15:00 EEST | Business Wire | Press release
Maropost, the commerce software suite built for fast-growing commerce brands, announces two significant appointments to its senior leadership team: Tim Schulz joins as VP of Product, Commerce Cloud, and Alessandra "Alex" Jacques steps in as VP of Product, Marketing Cloud.
"I founded Maropost to disrupt a crowded market, and with Tim and Alex on board, we are aggressively pursuing that vision," said Maropost Chairman and CEO Ross Andrew Paquette. "We're building a single platform that puts fast-growing retailers in control of their customer journeys, from hyper-personalized marketing to in-store and online purchases through exceptional service.
"Brands will use Maropost to create and manage product catalogs, centrally design and deploy promotions across all their channels, build engaging storefronts, and deliver personalized shopping experiences from one data set, in one nerve center."
Paquette is confident Maropost will achieve this mission. "We're not just another player in the market; we're here to redefine it. Watch closely: We're about to show what's possible when ingenuity meets determination."
About the New Appointees
Alex Jacques brings deep product management expertise from her roles at Terminus and Cheetah Digital. A certified CSM and CSPO, she excels at leading highly functional scrum teams, managing multiple platforms, and driving customer experience strategies. Her marketing technology prowess will shape the future of Marketing Cloud.
Tim Schulz is a seasoned product and technology leader with a track record of delivering outstanding results. As Head of Product at Magento and VTEX, he built products that enabled mid-market and enterprise retailers to scale their businesses globally and respond to shifts in the industry. At BigCommerce, he led Product & Engineering and grew revenue to over $100 million ARR in 24 months while launching strategic partnerships with top tech companies, including Facebook, Twitter, Google, and Alibaba.
Tim was also a top 5% performer at Google, where he led global platform partnerships for Google Shopping and drove 40 full-cycle enterprise deals across product lines. At Maropost, Tim will direct the development of future commerce products.
"We're thrilled to welcome Alex and Tim to the Maropost team," said Sean Brady, COO and President of Maropost. "Their extensive product expertise, proven leadership, and passion for delivering exceptional customer experiences will help us realize our vision of a unified platform that helps them grow, scale, and drive real value from their marketing, commerce, and service efforts."
About Maropost
Only Maropost unites the commerce tools and insights growing brands need to engage customers and scale their business. Built on unified customer data and an enterprise-grade infrastructure, Maropost offers a complete, connected suite of marketing, merchandising and search, customer service, ecommerce, and retail solutions.
Since its founding in 2011, Maropost has made multiple appearances on Deloitte's Technology Fast 500 list and G2's leaderboard. A global company, Maropost proudly serves 5,000+ leading commerce brands across North America, Australia, and Europe, including Victoria Beckham, Sandro Paris, Untuckit, Scott Sports, James Perse, and Fujifilm.
Learn more at www.maropost.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240521528910/en/
Contact information
Rob Wade
(888) 438-3152
press@maropost.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Provides Progress Update Regarding RelabotulinumtoxinA Regulatory Submission in the United States1.7.2026 08:00:00 EEST | Press release
Galderma (SIX: GALD) today provided progress updates regarding the regulatory review of its pending Biologics License Application (“BLA”) for RelabotulinumtoxinA with the U.S. Food and Drug Administration (“FDA”). The Company has received a Complete Response Letter (CRL) from the FDA with comments related to observations during manufacturing site inspection and analytical method optimization. As part of its review, the FDA conducted a Pre-License Inspection (PLI) of Galderma’s manufacturing site. All other aspects of the BLA, including safety- and efficacy-related parts, did not solicit deficiencies to be addressed. The FDA made observations during the PLI for which Galderma is putting in place corrective and preventive actions. Galderma will also be seeking further guidance through continued open dialogue with the FDA toward resolution of the relevant observations. Galderma plans to rapidly respond to the CRL and advancing RelabotulinumtoxinA in the U.S. remains a top priority. The ob
EVE Energy Showcases All-Scenario Energy Storage Solutions at The Smarter E Europe 20261.7.2026 04:45:00 EEST | Press release
EVE Energy unveiled its Mr. Big Family series, a 6.9+ MWh energy storage system, and all-scenario energy storage solutions at Intersolar Europe in Munich. Drawing on traceable large-cell technology, proven large-scale energy storage project delivery experience, and global delivery capabilities, the company is addressing Europe's diverse energy storage requirements across utility-scale, commercial & industrial (C&I ), and data center segments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260630889717/en/ EVE Energy showcases its Mr. Giant 3.0 6.9+ MWh energy storage system at The Smarter E Europe 2026 in Munich, Germany Advancing Large-Cell Technology with Global Project Validation As one of the first companies to focus on large-capacity energy storage cells, EVE Energy has iteratively upgraded its cell platform from 560 Ah and 628 Ah to 702 Ah, adhering to a stacking process route throughout. At the exhibition, the Mr. Gia
Bending Spoons S.p.A. announces pricing of initial public offering1.7.2026 02:56:00 EEST | Press release
Bending Spoons S.p.A. (“Bending Spoons”), a leading technology company, today announces the pricing of its initial public offering (“IPO”) at $29.00 per share. A total of 57,971,015 ordinary shares are being offered, of which 34,398,640 shares are being offered by Bending Spoons and 23,572,375 shares are being offered by certain selling shareholders (the “Selling Shareholders”). Bending Spoons will not receive any proceeds from any sale of shares by the Selling Shareholders. The shares are expected to begin trading on the Nasdaq Global Select Market under the ticker symbol “BSP” on July 1, 2026. The offering is expected to close on July 2, 2026, subject to customary closing conditions. In addition, Bending Spoons and the Selling Shareholders granted the underwriters an option to purchase up to an additional 5,244,026 ordinary shares from Bending Spoons and up to an additional 3,451,626 ordinary shares from the Selling Shareholders at the initial public offering price, less underwriting
FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 19:19:00 EEST | Press release
Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease and lung cancer,” she added. “More broadly, it reinforces the agency’s science-based approach to evaluating products across the co
Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 18:00:00 EEST | Press release
Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom